ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA)
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
Click here for more information: https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
What Can You Do?
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/adma-biologics-inc
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/adma-biologics-inc
Attorney advertising. Past results do not guarantee future outcomes.
Previous Posts:
- HUNTINGTON INGALLS ALERT: Bragar Eagel & Squire, P.C. is Investigating Huntington Ingalls Industries, Inc. on Behalf of Huntington Ingalls Stockholders and Encourages Investors to Contact the Firm
- LILIUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Lilium N.V. and Encourages Investors to Contact the Firm
- XEROX ALERT: Bragar Eagel & Squire, P.C. is Investigating Xerox Holdings Corporation on Behalf of Xerox Stockholders and Encourages Investors to Contact the Firm
Next Posts:
- GLOBE LIFE ALERT: Bragar Eagel & Squire, P.C. is Investigating Globe Life, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- PACS INVESTOR UPDATE: Did PACS Group, Inc. Mislead Investors Causing Losses? Contact BFA Law about its Pending Securities Fraud Investigation (NYSE:PACS)
- ACHC INVESTOR UPDATE: Did Acadia Healthcare Mislead Investors Causing Losses? Contact BFA Law about its Pending Securities Fraud Lawsuit (Nasdaq:ACHC)
